The following table details the insider trading activities
(stock purchases, stock sales, and stock option exercises) of Winslow Garrett since 2020.
This trader's CIK number is 1803773.
At the time of last reporting, Winslow Garrett was the General Counsel of Damora Therapeutics, Inc.. (stock ticker symbol DMRA).
Also see all insider trading activities at Damora Therapeutics, Inc..
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2020 | SBPH | 0 | $0 | 175 | $833 | 6,250 | $0 |
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2026 | DMRA | 0 | $0 | 500 | $12,796 | 1,360 | $0 |
| 2025 | DMRA | 0 | $0 | 731 | $3,518 | 2,000 | $0 |
| 2021 | DMRA | 4,000 | $14,560 | 0 | $0 | 0 | $0 |
1. F-star Therapeutics, Inc. (SBPH)
2. Damora Therapeutics, Inc. (DMRA)
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2020-11-19 | SBPH | Option Ex | 6,250 | .00 | 0 |
| 2020-11-20 | SBPH | Sale | 175 | 4.76 | 833 |
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2026-07-06 | DMRA | Sale | 245 | 29.98 | 7,345 |
| 2026-07-03 | DMRA | Option Ex | 680 | .00 | 0 |
| 2026-01-02 | GLTO | Option Ex | 680 | .00 | 0 |
| 2026-01-02 | GLTO | Sale | 255 | 21.38 | 5,451 |
| 2025-07-03 | GLTO | Option Ex | 680 | .00 | 0 |
| 2025-07-03 | GLTO | Sale | 260 | 3.39 | 881 |
| 2025-01-03 | GLTO | Option Ex | 1,320 | .00 | 0 |
| 2025-01-03 | GLTO | Sale | 471 | 5.60 | 2,637 |
| 2021-12-03 | GLTO | Buy | 2,000 | 2.48 | 4,960 |
| 2021-06-23 | GLTO | Buy | 2,000 | 4.80 | 9,600 |
Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Winslow Garrett (General Counsel of Damora Therapeutics, Inc. at the time of this reporting) see the Securities and Exchange Commission (SEC) website.